Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ramsin Benyamin

Interventional Pain Medicine Bloomington, IL Medical Doctor

NPI 1215924410 CMS profile 99927

1015 S Mercer Ave, Bloomington, IL 61701

Open in the dashboard

General payments

$31,884

263 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$80,000

1 holding reported · through program year 2024

Research they led as principal investigator

$3,245 paid to institutions, not to them · program years 2020–2022

Through program year 2024, Ramsin Benyamin of Bloomington, IL is reported in the CMS Open Payments database as having received $31,884 across 263 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,245 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $80,000 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $202 2
2022 General $19 1
2021 General $146 6
2020 General $11,188 92
2019 General $20,329 162
2024 Ownership $80,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramsin Benyamin
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ramsin Benyamin were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ramsin Benyamin Interventional Pain Medicine median Middle half National median
2019 $20,329 $684 $216–$2,079 $163
2020 $11,188 $382 $122–$1,109 $114
2021 $146 $552 $167–$1,554 $132
2022 $19 $605 $187–$1,924 $149
2023 $0 $671 $195–$1,915 $160
2024 $202 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medtronic USA, Inc. $11,946 46 payments
  2. Vertiflex, Inc. $8,975 19 payments
  3. Avanos Medical $6,448 6 payments
  4. Abbott Laboratories $1,268 48 payments
  5. Flowonix Medical Incorporated $456 1 payment
  6. Teva Pharmaceuticals USA, Inc. $399 31 payments
  7. Boston Scientific Corporation $315 8 payments
  8. Allergan Inc. $295 20 payments
  9. TerSera Therapeutics LLC $276 14 payments
  10. Stimwave Technologies Incorporated $180 1 payment
  11. Other $1,324 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $12,636 4 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,250 3 payments
  3. Food and Beverage $7,165 245 payments
  4. Travel and Lodging $4,377 10 payments
  5. Entertainment $456 1 payment
Products named General payments · program years 2019–2024
  1. INTELLIS $11,503 35 payments
  2. Superion ISS $8,975 19 payments
  3. COOLIEF* COOLED RADIOFREQUENCY $6,425 5 payments
  4. Proclaim Family of SCS IPGs $605 5 payments
  5. Prometra II $456 1 payment
  6. Neuromodulation Dspsbls and Accs $445 41 payments
  7. PRIALT $276 14 payments
  8. Ajovy $264 17 payments
  9. SUPERION $235 6 payments
  10. BOTOX $210 14 payments
  11. Other $2,455 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

23

Median for Interventional Pain Management: 1,220

Drug cost

$477

Median for Interventional Pain Management: $39,344

Branded share of claims

52.2%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $392
Pregabalin Generic 11 $86

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record